Dr. Shah on BCMA-Directed CAR T-Cell Therapy Research in R/R Multiple Myeloma

Video

Nina Shah, MD, discusses ​ongoing research with BCMA-directed CAR T-cell therapy in relapsed/refractory multiple myeloma.

Nina Shah, MD, a hematologist and associate professor of medicine, Department of Medicine, at the University of California, San Francisco (UCSF) Helen Diller Family Comprehensive Cancer Center, discusses ​ongoing research with BCMA-directed CAR T-cell therapy in relapsed/refractory multiple myeloma.

Idecabtagene vicleucel (ide-cel; bb2121) and JNJ-4528 are similar in the way they target BCMA and intracellularly signal 4-1BB, Shah explains. This could be very beneficial to patients with multiple myeloma as BCMA is uniformly expressed on ​myeloma plasma cells.

However, these products differ in terms of structure​, Shah adds. For example, the BCMA-directed component of ide-cel attaches to 2 different parts of the target.

Notably, recent findings suggest that ​even patients ​with low levels of BCMA can respond to BCMA-directed CAR T-cell therapy, Shah concludes.

Recent Videos
Jeffrey Chamberlain, PhD
Tami John, MD
Tami John, MD
Tami John, MD
Matthew Ku, MBBS, FRACP, RACP, FRCPA/RCPA, PhD, an associate professor and the lymphoma stream lead at St Vincent’s Hospital
Saurabh Dahiya, MD, FACP, an associate professor of medicine at Stanford University School of Medicine; as well as clinical director of Cancer Cell Therapy in the Division of Blood and Marrow Transplantation and Cell Therapy at Stanford Medicine
Shahzad Raza, MD, a hematologist/oncologist at the Cleveland Clinic
Manali Kamdar, MD, the associate professor of medicine–hematology and clinical director of lymphoma services at the University of Colorado
Shahzad Raza, MD, a hematologist/oncologist at the Cleveland Clinic
Laura Aguilar MD, PhD, the chief medical officer of Diakonos Oncology
Related Content
© 2025 MJH Life Sciences

All rights reserved.